KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Long-Term Debt Issuances (2020 - 2026)

Amneal Pharmaceuticals has reported Long-Term Debt Issuances over the past 1 years, most recently at $180.0 million for Q1 2020.

For Q1 2020, Long-Term Debt Issuances changed N/A year-over-year to $180.0 million; the TTM value through Dec 2020 reached $180.0 million, changed N/A, while the annual FY2025 figure was $2.7 billion, N/A changed from the prior year.
Long-Term Debt Issuances for Q1 2020 was $180.0 million at Amneal Pharmaceuticals.
Over five years, Long-Term Debt Issuances peaked at $180.0 million in Q1 2020 and troughed at $180.0 million in Q1 2020.